Evolocumab and clini- cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713 22. S3.2.2-6. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a ran- domized trial of evolocumab. N Engl J Med. 2017;377:633 43. 3.2.3. Nonstatin Add-on Drugs to Statin Therapy S3.2.3-1. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372:2387 97. S3.2.3-2. Jacobson TA, Ito MK, Maki KC, et al. National lipid association rec- ommendations for patient-centered management of dyslipidemia: part 1 full report. J Clin Lipidol. 2015;9:129 69. S3.2.3-3. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of ali- rocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186 94. S3.2.3-4. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500 9. 4. PATIENT MANAGEMENT GROUPS 4.1. Secondary ASCVD Prevention S4.1-1. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549 59. S4.1-2. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220 8. S4.1-3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S4.1-4. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532 61. S4.1-5. 